Go to Top
INVENTOR LOGIN

Details

Project TitleMucosal Dry Powder Vaccination Strategies against Infectious Diseases
Track Code2014-111
Short Description

A method for needle-free vaccination, which can be administered orally or by the pulmonary route.

Abstract

This formulation allows for an increased length of time that the vaccine remains viable under non-refrigerated, ambient temperature conditions. These dry powder vaccines can be delivered using a pill or a capsule and thus represents a significant delivery improvement over existing injected liquid vaccines. Furthermore, the material used to encapsulate these bacterial vaccines into a protective matrix is already FDA approved.

 
Tagsneedle-free, vaccination
 
Posted DateJul 11, 2014 1:37 PM

Researcher

Name
Nitesh Kunda
Pavan Muttil
Terry Wu
Denis Wafula
Dominique Price

Manager

Name
Jovan Heusser

Background

Vaccines save millions of lives each year and are among the most cost-effective health interventions developed.  Despite these great strides, there remains an urgent need to reach all children and adults with life-saving vaccines. Immunizations avert an estimated 2.5 million deaths each year around the world. However, an estimated 22.6 million infants worldwide are still missing out on basic vaccines. Unreliable transportation systems and storage facilities make it difficult to preserve high-quality vaccines that require constant refrigeration. Typical liquid vaccines can be particularly difficult as they must be stored at lower than room temperature at all times. This is not possible in many parts of the world, especially in developing countries. There is an urgent need for technologies that can provide vaccines that are easily transportable and that can remain viable for a longer period of time without refrigeration. 

Technology Description

Researchers at the University of New Mexico have developed a method for needle-free vaccination, which can be administered orally or by the pulmonary route. In addition, this formulation allows for an increased length of time that the vaccine remains viable under non-refrigerated, ambient temperature conditions. These dry powder vaccines can be delivered using a pill or a capsule and thus represents a significant delivery improvement over existing injected liquid vaccines. Furthermore, the material used to encapsulate these bacterial vaccines into a protective matrix is already FDA approved.

Advantages/Applications

  • Low cost, easily scalable and a one-step continuous process for production of these thermostable vaccines
  • Needle-free administration
  • Heat-stable
  • Viable for >6 months
  • Can be kept at room temperature
  • No sterile manufacturing of the vaccine is necessary
  • Material used to encapsulate vaccines are FDA approved
  • Suited for immunization in resource poor countries where cold-chain storage is highly unpredictable as well as in military emergencies and biodefense

Publications

Videos

INQUIRES

STC has filed intellectual property on this exciting new technology and is currently exploring commercialization options. If you are interested in information about this or other technologies, please contact Arlene Mirabal at amirabal@stc.unm.edu or 505-272-7886.

Files

File Name Description
US-2017-0112912-A1 Published Patent Application None Download